Therapeutic potential of RAS prenylation pharmacological inhibitors in the treatment of breast cancer, recent progress, and prospective. Issue 5 (30th October 2018)

• Record Type: Journal Article
• Authors: Soleimani, Atena; Amirinejad, Mostafa; Rahsepar, Sara; Vazirian, Fatemeh; Bahrami, Afsane; Ferns, Gordon A.; Khazaei, Majid; Avan, Amir; Hassanian, Seyed Mahdi
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 5(2019)
• Page Start: 6860
• Page End: 6867
• Publication Date: 2018-10-30
• Subjects: breast cancer (BC) -- farnesyltransferase inhibitors (FTI) -- geranylgeranyl transferase (GGTase) inhibitors -- RAS prenylation; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.27992
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Breast cancer is one of the most prevalent malignancies among women around the world. RAS proteins require posttranslational modifications, including protein prenylation for proper membrane localization and signaling. Regulation of RAS signaling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach in breast cancer therapy. This review summarizes the recent knowledge about the clinical value of RAS prenylation pharmacological inhibitors in breast cancer treatment. Abstract : RAS proteins require posttranslational modifications, including protein prenylation for proper membrane localization and signaling. Regulation of RAS signaling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach in breast cancer therapy. This review summarizes the recent knowledge about the clinical value of RAS prenylation pharmacological inhibitors in breast cancer treatment.